Fibrinogen–albumin ratio index (FARI): a more promising inflammation-based prognostic marker for patients undergoing hepatectomy for colorectal liver metastases
YY Wang, ZZ Liu, D Xu, M Liu, K Wang… - Annals of Surgical …, 2019 - Springer
Background Systemic inflammation response is involved in the development and
progression of cancers. This study aimed to evaluate the prognostic value of a preoperative …
progression of cancers. This study aimed to evaluate the prognostic value of a preoperative …
Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives
T Mizukami, N Izawa, TE Nakajima, Y Sunakawa - Drugs, 2019 - Springer
The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …
Colorectal cancer biomarkers in the era of personalized medicine
JN Patel, MK Fong, M Jagosky - Journal of personalized medicine, 2019 - mdpi.com
The 5-year survival probability for patients with metastatic colorectal cancer has not
drastically changed over the last several years, nor has the backbone chemotherapy in first …
drastically changed over the last several years, nor has the backbone chemotherapy in first …
Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling …
Y Yu, D Chen, T Wu, H Lin, L Ni, H Sui, S Xiao, C Wang… - Phytomedicine, 2022 - Elsevier
Background Globally, colorectal cancer (CRC) is one of the leading causes of cancer-
related deaths. Oxaliplatin based treatments are frequently used as chemotherapeutic …
related deaths. Oxaliplatin based treatments are frequently used as chemotherapeutic …
Construction and validation of nomograms combined with novel machine learning algorithms to predict early death of patients with metastatic colorectal cancer
Y Zhang, Z Zhang, L Wei, S Wei - Frontiers in Public Health, 2022 - frontiersin.org
Purpose The purpose of this study was to investigate the clinical and non-clinical
characteristics that may affect the early death rate of patients with metastatic colorectal …
characteristics that may affect the early death rate of patients with metastatic colorectal …
[HTML][HTML] Emerging actionable targets to treat therapy-resistant colorectal cancers
E Grassilli, MG Cerrito - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
In the last two decades major improvements have been reached in the early diagnosis of
colorectal cancer (CRC) and, besides chemotherapy, an ampler choice of therapeutic …
colorectal cancer (CRC) and, besides chemotherapy, an ampler choice of therapeutic …
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild‐Type Unresectable Liver Metastases Colorectal Cancer …
H Hu, K Wang, M Huang, L Kang, W Wang… - The …, 2021 - academic.oup.com
Purpose This trial evaluated the addition of cetuximab to a modified FOLFOXIRI
(mFOLFOXIRI: 5‐fluorouracil/folinic acid, oxaliplatin, irinotecan) as conversion therapy in a …
(mFOLFOXIRI: 5‐fluorouracil/folinic acid, oxaliplatin, irinotecan) as conversion therapy in a …
Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers
N Wang, B Pei, X Yuan, C Yi… - … in Bioengineering and …, 2022 - frontiersin.org
Gastrointestinal tumours are the most common solid tumours, with a poor prognosis and
remain a major challenge in cancer treatment. Mesenchymal stem cells (MSC) are …
remain a major challenge in cancer treatment. Mesenchymal stem cells (MSC) are …
A meta-analysis to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC)
Recent trials provide evidence that HER2 is a potential new target for patients with colorectal
cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2 …
cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2 …
[HTML][HTML] NeoRAS wild-type in metastatic colorectal cancer: myth or truth?—Case series and review of the literature
H Osumi, L Vecchione, U Keilholz, C Vollbrecht… - European Journal of …, 2021 - Elsevier
Upfront KRAS and NRAS gene testing ('RAS') is the standard of care for metastatic
colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) …
colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) …